Article
Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for “prime time”?
24 Nov 2014
Abstract excerpt
The past 40 years have witnessed major advances in defining the cytogenetic aberrations, mutational landscape, epigenetic profiles, and expression changes underlying hematological malignancies. Although it has become apparent that acute myeloid leukemia (AML) is highly heterogeneous at the molecular level, the standard framework for risk stratification guiding transplant practice in this disease remains largely...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.